BMS Is Latest To Join Synthetic Lethality Bandwagon With Volastra Deal

 
• By Alaric DeArment

Deal Snapshot: The drug maker is betting $30m up front and up to $1.1bn in milestone fees for an increasingly popular approach to oncology drug development.

Cancer - DNA - test tube
BMS signed a deal with Volastra focused on synthetic lethality in oncology • Source: Shutterstock

Who: Bristol Myers Squibb/Volastra Therapeutics

What: The two companies signed a deal whereby Volastra will conduct various activities for targets that remain undisclosed using its CINtech platform, with BMS taking up

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas